X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Fulford India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs FULFORD INDIA - Comparison Results

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA FULFORD INDIA SHASUN PHARMA/
FULFORD INDIA
 
P/E (TTM) x 123.9 398.8 31.1% View Chart
P/BV x 8.5 6.2 137.3% View Chart
Dividend Yield % 0.2 0.1 275.4%  

Financials

 SHASUN PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
FULFORD INDIA
Mar-14
SHASUN PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs94942 10.0%   
Low Rs46450 10.1%   
Sales per share (Unadj.) Rs214.2691.4 31.0%  
Earnings per share (Unadj.) Rs5.311.5 46.6%  
Cash flow per share (Unadj.) Rs15.815.4 103.0%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %1.40.3 497.9%  
Book value per share (Unadj.) Rs53.3380.0 14.0%  
Shares outstanding (eoy) m56.623.90 1,451.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.0 32.4%   
Avg P/E ratio x13.160.7 21.6%  
P/CF ratio (eoy) x4.445.3 9.8%  
Price / Book Value ratio x1.31.8 71.5%  
Dividend payout %18.717.4 107.4%   
Avg Mkt Cap Rs m3,9582,714 145.8%   
No. of employees `000NA0.4 0.0%   
Total wages/salary Rs m2,164505 428.4%   
Avg. sales/employee Rs ThNM6,073.0-  
Avg. wages/employee Rs ThNM1,137.4-  
Avg. net profit/employee Rs ThNM100.7-  
INCOME DATA
Net Sales Rs m12,1272,696 449.7%  
Other income Rs m229125 182.9%   
Total revenues Rs m12,3562,822 437.9%   
Gross profit Rs m1,009-46 -2,174.7%  
Depreciation Rs m59415 3,905.3%   
Interest Rs m41510 4,369.5%   
Profit before tax Rs m23054 423.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-7310 -757.5%   
Profit after tax Rs m30245 675.9%  
Gross profit margin %8.3-1.7 -483.5%  
Effective tax rate %-31.717.7 -179.1%   
Net profit margin %2.51.7 150.3%  
BALANCE SHEET DATA
Current assets Rs m6,8841,738 396.0%   
Current liabilities Rs m8,456545 1,552.4%   
Net working cap to sales %-13.044.3 -29.3%  
Current ratio x0.83.2 25.5%  
Inventory Days Days6248 127.2%  
Debtors Days Days1084 2,498.4%  
Net fixed assets Rs m4,97012 41,766.4%   
Share capital Rs m11339 290.5%   
"Free" reserves Rs m2,8751,443 199.2%   
Net worth Rs m3,0201,482 203.8%   
Long term debt Rs m1,8170-   
Total assets Rs m13,3472,077 642.7%  
Interest coverage x1.66.7 23.1%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.91.3 70.0%   
Return on assets %5.42.6 205.9%  
Return on equity %10.03.0 331.7%  
Return on capital %13.34.3 309.5%  
Exports to sales %46.40-   
Imports to sales %14.224.5 58.3%   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728659 262.1%   
Fx inflow Rs m5,84317 33,968.6%   
Fx outflow Rs m2,173673 322.8%   
Net fx Rs m3,669-656 -559.4%   
CASH FLOW
From Operations Rs m39890 441.8%  
From Investments Rs m-1,635105 -1,563.1%  
From Financial Activity Rs m1,309-14 -9,280.9%  
Net Cashflow Rs m71181 39.4%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.6 3.8 94.7%  
FIIs % 17.6 0.1 17,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 21.2 186.8%  
Shareholders   20,750 4,783 433.8%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   MERCK LTD  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS